thefederalregister.org Federal Register Research Archive

Document

Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction

The Food and Drug Administration is correcting a notice entitled "Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal" that appeared in the Federal Re...

PDF versionSource Record
Department of Health and Human Services
Food and Drug Administration
  1. [Docket No. FDA-2018-N-3091]

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice; correction.

SUMMARY:

The Food and Drug Administration is correcting a notice entitled “Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal” that appeared in the Federal Register of December 13, 2022. The document announced the renewal of the ( printed page 1600) Cardiovascular and Renal Drugs Advisory Committee. The document was published with the incorrect docket number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT:

Lisa Granger, Office of Policy, Planning, Legislation and International Affairs, Food and Drug Administration, 301-796-9115, .

SUPPLEMENTARY INFORMATION:

In the Federal Register of Tuesday, December 13, 2022 (87 FR 76197), in FR Doc. 2022-27014, on page 76197 the following correction is made:

1. On page 76197, in the first column of the header of the document, “Docket No. FDA-2022-N-3091” is corrected to read “Docket No. FDA-2018-N-3091”.

Dated: January 3, 2023.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2023-00390 Filed 1-10-23; 8:45 am]

BILLING CODE 4164-01-P

Legal Citation

Federal Register Citation

Use this for formal legal and research references to the published document.

88 FR 1599

Web Citation

Suggested Web Citation

Use this when citing the archival web version of the document.

“Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction,” thefederalregister.org (January 11, 2023), https://thefederalregister.org/documents/2023-00390/advisory-committee-cardiovascular-and-renal-drugs-advisory-committee-renewal-correction.